Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetone in vitro

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11160%2F13%3A10144044" target="_blank" >RIV/00216208:11160/13:10144044 - isvavai.cz</a>

Result on the web

<a href="http://informahealthcare.com/doi/full/10.3109/00498254.2012.720048" target="_blank" >http://informahealthcare.com/doi/full/10.3109/00498254.2012.720048</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3109/00498254.2012.720048" target="_blank" >10.3109/00498254.2012.720048</a>

Result language

angličtina

Original language name

Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetone in vitro

Original language description

1. Nabumetone is a clinically used non-steroidal anti-inflammatory drug, its biotransformation includes major active metabolite 6-methoxy-2-naphtylacetic acid and another three phase I as well as corresponding phase II metabolites which are regarded as inactive. One important biotransformation pathway is carbonyl reduction, which leads to the phase I metabolite, reduced nabumetone. 2. The aim of this study is the determination of the role of a particular human liver subcellular fraction in the nabumetone reduction and the identification of participating carbonyl reducing enzymes along with their stereospecificities. 3. Both subcellular fractions take part in the carbonyl reduction of nabumetone and the reduction is at least in vitro the main biotransformation pathway. The activities of eight cytosolic carbonyl reducing enzymes - CBR1, CBR3, AKR1B1, AKR1B10, AKR1C1-4 - toward nabumetone were tested. Except for CBR3, all tested reductases transform nabumetone to its reduced metabolite. A

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

CE - Biochemistry

OECD FORD branch

—

Project

<a href="/en/project/EE2.3.20.0235" target="_blank" >EE2.3.20.0235: Establishment of Research Team Focused on Experimental and Applied Biopharmacy</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2013

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Xenobiotica

ISSN

0049-8254

e-ISSN

—

Volume of the periodical

43

Issue of the periodical within the volume

4

Country of publishing house

AU - AUSTRALIA

Number of pages

9

Pages from-to

346-354

UT code for WoS article

000315636400004

EID of the result in the Scopus database

—